Cystic Fibrosis Research and Translation Center
Cystic Fibrosis Research and Translation Center
Request Core Services Request Core Services Request Core Services
Request Core Services

Upcoming Events

No featured events at this time.


Upcoming Events

Pilot Applications Due Date
Monday, March 17, 2014
All Day

Download PDF

FOR FURTHER INFORMATION CONTACT:
Dr. Bonnie Ramsey, Professor, Pediatrics (987-5725) bonnie.ramsey@seattlechildrens.org
Dr. Pete Greenberg, Professor, Microbiology (616-2881) epgreen@u.washington.edu
Dr. Ronald Gibson, Professor, Pediatrics (987-3025) ron.gibson@seattlechilrens.org
Dr. Colin Manoil, Professor, Genome Sciences (543-7800) manoil@uw.edu

The NIH P30 Cystic Fibrosis Research Translation Center (CFRTC) is seeking applications for Pilot and Feasibility Studies focused on development and/or translation of promising laboratory findings that may lead to novel therapies for individuals with cystic fibrosis (CF).

Pilot and Feasibility applications will be awarded on 6/1/14, for up to 2 years at $40,000 - $75,000 direct costs per year (2nd year funding pending approval of competitive renewal starting 6/1/15).  Investigators eligible for pilot and feasibility funding generally fall into three categories: (1) new investigators without current or past NIH research support as a principal investigator; (2) established investigators with no previous work in CF who wish to apply their expertise to a problem in this area; and (3) established investigators who propose testing innovative ideas that represent clear departure from ongoing research interests. Each pilot and feasibility study proposal should state clearly the justification for eligibility of the investigator under one of the above three criteria.

 Examples of relevant research topics are:

1. Promote and expedite the translation of basic laboratory observations into a) better understanding of clinical disease b) improved diagnostic tools for assessing early disease manifestations in CF and/or c) new therapeutic approaches for treating gastrointestinal, hepatic, metabolic (including CF related diabetes mellitus) and lung disease in CF.
2. Better understand the impact of bacterial genetic factors and phenotypic characteristics on progression of CF lung disease and GI health and utilize these findings to develop improved therapeutic approaches.
3. Better understand host inflammatory responses to bacterial infection to optimize anti-inflammatory and anti-infective approaches.
4. Better understand early infection in infants diagnosed with CF through newborn screening.

Applicants should use PHS 398 forms (http://grants.nih.gov/grants/funding/phs398/phs398.html) for completing this application including face page, abstract, detailed budget and justification, biosketch, other support, resources, planned enrollment (for clinical studies) and research plan (limited to 5 pages not including reference).  Applications must be submitted by March 17, 2014 to Donna Crist at donna.crist@seattlechildrens.org




powered by hang wire